Inevica

Active Ingredient:: Ivabradine
Origin:: EU

Inevica (Ivabradine)

Q: What is Inevica used for?

Inevica contains ivabradine and is prescribed to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction. By controlling heart rate, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Q: How does ivabradine work?

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for the spontaneous depolarisation that sets the heart’s rhythm. Inhibiting this current slows the pacemaker activity, reducing resting heart rate without affecting the strength of cardiac contraction.

Q: What is the usual dose of Inevica?

The dose of Inevica is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response and tolerance. The prescriber will select an appropriate starting dose and may adjust it during follow‑up to achieve the desired heart‑rate target.

Q: Is Inevica safe in pregnancy or breastfeeding?

Safety of ivabradine during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

Q: How do I order Inevica from GNH India?

To request Inevica, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Inevica compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but beta‑blockers also reduce myocardial contractility and blood pressure. Ivabradine specifically targets the If current, offering heart‑rate reduction without negative inotropic effects, making it useful when beta‑blockers are contraindicated or insufficient.

Q: What are the storage and handling requirements for Inevica?

Inevica should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and out of reach of children.

Q: How is Inevica administered?

Inevica is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed.

Q: What are the most serious risks associated with Inevica?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, heart block and worsening heart failure. Patients should be monitored for signs of these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Q: Who should not use Inevica?

Inevica is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, and those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Inevica, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Inevica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global patients.

Manufacturer / TM Owner

Actavis Group Ptc Ehf.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If current to manage conditions characterized by elevated heart rate.
Chronic stable angina pectoris: improves exercise tolerance and reduces frequency of angina episodes.
Heart failure with reduced ejection fraction (HFrEF): lowers resting heart rate, alleviates symptoms and may decrease hospitalisation risk.
Ischemic heart disease: helps control heart rate when beta‑blockers are insufficient or not tolerated.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows the spontaneous depolarisation of pacemaker cells. By reducing the slope of phase 4 depolarisation, the drug lowers heart rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, providing a heart‑rate‑focused therapeutic effect.

Side Effects

Common Side Effects

Bradycardia: unusually slow heart rate.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache: mild to moderate intensity.
Dizziness or light‑headedness.
Fatigue or general weakness.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other significant arrhythmias.
Severe hypotension.
Symptomatic heart block.
Worsening heart failure.
Allergic reactions such as rash, angioedema or anaphylaxis.

Precautions & Warnings

Ivabradine should be used with careful clinical assessment and monitoring.
Cardiac monitoring: obtain baseline heart rate and ECG before initiation.
Contraindicated in severe hypotension: avoid use when systolic BP <90 mmHg.
Avoid in patients with sick sinus syndrome or atrioventricular block.
Caution in hepatic impairment: dose adjustment may be required.
Avoid concomitant strong CYP3A4 inhibitors: may increase drug exposure.
Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
Concomitant bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction.
Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy.
Verapamil or diltiazem: moderate increase in ivabradine concentrations.
Alcohol: can enhance bradycardic effect, especially in susceptible patients.

Frequently Asked Questions

Inevica contains ivabradine and is prescribed to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction. By controlling heart rate, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for the spontaneous depolarisation that sets the heart’s rhythm. Inhibiting this current slows the pacemaker activity, reducing resting heart rate without affecting the strength of cardiac contraction.

The dose of Inevica is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response and tolerance. The prescriber will select an appropriate starting dose and may adjust it during follow‑up to achieve the desired heart‑rate target.

Safety of ivabradine during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Inevica, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but beta‑blockers also reduce myocardial contractility and blood pressure. Ivabradine specifically targets the If current, offering heart‑rate reduction without negative inotropic effects, making it useful when beta‑blockers are contraindicated or insufficient.

Inevica should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and out of reach of children.

Inevica is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, heart block and worsening heart failure. Patients should be monitored for signs of these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Inevica is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, and those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 08 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.